2-(2-aminopropan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide

We are 2-(2-aminopropan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide CAS:518048-03-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name:
2-(2-aminopropan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide
Synonym: Intermediate of Raltegravir; 6-dihydropyrimidine-4-carboxamide;
2-(1-amino-1-methyl-ethyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid 4-fluoro-benzylamide
Cas No.: 518048-03-8
Formula: C16H19FN4O3
MW: 334.35
EINECS No.: 1592732-453-0

Density: 1.4±0.1 g/cm3
Boiling point: 567.4ºC at 760 mmHg
Melting point: 105-107ºC
Flash point: 311ºC
Refractive index: 1.607

HS Code: 2933599090 

UN No.: N.A
Hazard class: Non-dangerous goods
 
Specification

Items of Analysis Standard of Analysis Test Results
Appearance White or similar white powder Conforms
Purity (HPLC) ≥99%  99.75%
Single Impurity ≤1.0% 0.07%
Total impurities ≤1.0% 0.25%
Loss on drying ≤0.5% 0.12%
Residue on Ignition ≤0.15% 0.13%
Conclusion Conforms to Factory Standard

 
 
Application
An important intermediate for the synthesis of AIDS antiviral drug Raltegravir.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 

2-(2-aminopropan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide


Related News: Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.35480-52-5 API and raw material are often confused due to the similar usage of the two terms.4457-71-0 According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.202865-66-5 In terms of business, the industrial business increased by 7.97% year-on-year, while the revenue from the trading business shrank to a certain extent. The growth rate of industrial business was significantly slower than 24% in the first half of the year, showing that the growth rate of industrial business was lower in the third quarter, which was also the main reason for the decline in the company’s operating income in the third quarter. The company’s industrial business is mainly pesticide intermediates, accounting for about 85%. The scale of the pesticide intermediate business is large and the base is high, which is putting pressure on growth.In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.

Related Products
Product Name
1-Chloro-2-fluoro-3-isocyanatobenzene View Details
Dimethyl (3-(3-chlorophenoxy)-2-oxopropyl)phosphonate View Details
2-phenoxyethyl 4-aminobenzoate View Details
6-(trifluoromethyl)-1H-indole-2-carboxylic acid manufacturer Acetyl Tetrapeptide-2 manufacturer ac-asp(otbu)-oh manufacturer 4-bromoanisole manufacturer 1-Methyl-4-piperidone manufacturer